EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.21.61 | drug development | PCSK9 is a highly promising therapeutic target to lower low density lipoprotein-cholesterol and therefore prevent or reduce atherosclerosis | Homo sapiens |
EC Number | Cloned (Comment) | Organism |
---|---|---|
3.4.21.61 | wild-type PCSK9 with a V5 epitope flag inserted into pcDNA3.1. PCSK9 mutants expressed in primary hepatocytes derived from PCSK9-/- mice | Homo sapiens |
EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
3.4.21.61 | D374Y | naturally occurring gain-of-function mutation, associated to hypercholesterolemia and premature atherosclerosisias. Has less effect on processing (49% maturation) | Homo sapiens |
3.4.21.61 | F216L | naturally occurring gain-of-function mutation, associated to hypercholesterolemia and premature atherosclerosisias. Is matured to the same extent than the wild type (67% maturation) | Homo sapiens |
3.4.21.61 | S127R | naturally occurring gain-of-function mutation, associated to hypercholesterolemia and premature atherosclerosisias. Strongly diminishes processing (21% maturation) | Homo sapiens |
3.4.21.61 | S386A | catalytically inactive, strongly diminishes processing (8% maturation) | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.21.61 | Homo sapiens | Q8NBP7 | - |
- |
3.4.21.61 | Mus musculus | - |
- |
- |
EC Number | Purification (Comment) | Organism |
---|---|---|
3.4.21.61 | - |
Mus musculus |
3.4.21.61 | - |
Homo sapiens |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.21.61 | blood plasma | - |
Mus musculus | - |
3.4.21.61 | HEK-293 cell | - |
Homo sapiens | - |
3.4.21.61 | hepatocyte | - |
Mus musculus | - |
3.4.21.61 | hepatocyte | - |
Homo sapiens | - |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.21.61 | PCSK9 | - |
Mus musculus |
3.4.21.61 | PCSK9 | - |
Homo sapiens |
3.4.21.61 | pro-protein convertase subtilisin/kexin type 9 | - |
Mus musculus |
3.4.21.61 | pro-protein convertase subtilisin/kexin type 9 | - |
Homo sapiens |
EC Number | Organism | Comment | Expression |
---|---|---|---|
3.4.21.61 | Homo sapiens | knockdown of PCSK9 expression in immortalized human hepatocytes using specific siRNA which results in a 38% and 53% decrease in PCSK9 protein quantity, respectively in cell lysates and culture media compared with controls | down |
EC Number | General Information | Comment | Organism |
---|---|---|---|
3.4.21.61 | malfunction | at t = 585 min, PCSK9-/- hepatocytes exhibit 90% less activity than wild-type | Mus musculus |
3.4.21.61 | malfunction | cells with lower PCSK9 expression and secretion have a low density lipoprotein binding activity augmented by 200% | Homo sapiens |
3.4.21.61 | physiological function | high level of activity in wild-type PCSK9+/+ hepatocytes. At t = 585 min, the activity of 20 microg of total hepatocyte lysates is 360% higher than that of 10 microg of purified protein | Mus musculus |